Preview Mode Links will not work in preview mode

Sep 28, 2023

Featuring an interview with Dr Paul G Richardson, including the following topics:

  • Biologic rationale for targeting protein degradation pathways as a therapeutic approach in multiple myeloma (MM); mechanism of action of CELMoDs (0:00)
  • Similarities and differences between iberdomide, mezigdomide and standard immunomodulatory drugs (7:14)
  • Compassionate use of melflufen and belantamab mafodotin (12:08)
  • Current management strategies for newly diagnosed MM (16:30)
  • DETERMINATION: Evaluation of trial findings on racial and ethnic disparities and differential outcomes (23:02)
  • Tailoring of up-front daratumumab-based therapies; management of extramedullary disease (33:17)

CME information and select publications